• 1
    World Health Organization. Hepatitis C [fact sheet no. 164]. Updated October 2000. Available at: Accessed: February 23, 2007.
  • 2
    NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19 (3): 146.
  • 3
    Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 55662.
  • 4
    Howell C, Jeffers L, Hoofnagle JH. Hepatitis C in African Americans: summary of a workshop. Gastroenterology 2000; 119: 138596.
  • 5
    El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 74550.
  • 6
    Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000; 132: 10511.
  • 7
    Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998; 47 (RR-19): 139.
  • 8
    Bonilla J, Rosen L, for the Population Research Center. Black Americans: a demographic perspective [executive summary]. Updated: December, 2001. Available at Accessed: February 23, 2007.
  • 9
    Hyams KC, Riddle J, Rubertone M, et al. Prevalence and incidence of hepatitis C virus infection in the US military: a seroepidemiologic survey of 21,000 troops. Am J Epidemiol 2001; 153: 76470.
  • 10
    Vlahov D, Nelson KE, Quinn TC, Kendig N. Prevalence and incidence of hepatitis C virus infection among male prison inmates in Maryland. Eur J Epidemiol 1993; 9: 5669.
  • 11
    Ruiz JD, Molitor F, Sun RK, et al. Prevalence and correlates of hepatitis C virus infection among inmates entering the California correctional system. West J Med 1999; 170: 15660.
  • 12
    Sterling RK, Stravitz RT, Luketic VA, et al. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clin Gastroenterol Hepatol 2004; 2: 46973.
  • 13
    Pyrsopoulos N, Jeffers L. Chronic hepatitis C in African Americans. Clin Liver Dis 2005; 9: 42738.
  • 14
    Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 29: 90814.
  • 15
    Sugimoto K, Stadanlick J, Ikeda F, et al. Influence of ethnicity in the outcome of hepatitis C virus infection and cellular immune response. Hepatology 2003; 37: 5909.
  • 16
    Frese M, Schwärzle V, Barth K, et al. Interferon-γ inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology 2002; 35: 694703.
  • 17
    Wiley TE, Brown J, Chan J. Hepatitis C infection in African Americans: its natural history and histological progression. Am J Gastroenterol 2002; 97: 7006.
  • 18
    Reddy SI, Ukomadu C. Viral hepatitis and hepatocellular carcinoma in African Americans. Cancer Epidemiol Biomarkers Prev 2003; 12: 248s51s.
  • 19
    El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002; 36 (5 Suppl. 1): S7483.
  • 20
    Nguyen MH, Whittemore AS, Garcia RT, et al. Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin Gastroenterol Hepatol 2004; 2: 8204.
  • 21
    El-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 87107, vi.
  • 22
    Reddy KR, Hoofnagle JH, for the Consensus Interferon Study Group et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 1999; 30: 78793.
  • 23
    Kinzie JL, Naylor PH, Nathani MG, et al. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepat 2001; 8: 2649.
  • 24
    De Maria N, Colantoni A, Idilman R, Friedlander L, Harig J, Van Thiel DH. Impaired response to high-dose interferon treatment in African-Americans with chronic hepatitis C. Hepatogastroenterology 2002; 49: 78892.
  • 25
    Theodore D, Shiffman ML, Sterling RK, et al. Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis C. Dig Dis Sci 2003; 48: 1405.
  • 26
    Poynard T, Marcellin P, for the International Hepatitis Interventional Therapy Group (IHIT) et al. Randomised trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 142632.
  • 27
    McHutchison JG, Gordon SC, et al. for the Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 148592.
  • 28
    Manns MP, McHutchison JG, et al. and the International Hepatitis Interventional Therapy Group. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 95865.
  • 29
    Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 97582.
  • 30
    Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006; 131: 4707.
  • 31
    Jacobson I, Brown RJ, the the WIN-R Study Group et al. Weight based ribavirin dosing improves virologic response in HCV-infected genotype 1 African-Americans (AA) compared to flat dose ribavirin with peginterferon alfa-2b combination therapy [abstract 125]. Hepatology 2004; 40 (Suppl. 1): 217A.
  • 32
    Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 39: 17028.
  • 33
    Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites [Erratum in N Engl J Med 2004;351:1268]. N Engl J Med 2004; 350: 226571.
  • 34
    McHutchison JG, Poynard T, et al. for the International Hepatitis Interventional Therapy Group. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. Gastroenterology 2000; 119: 131723.
  • 35
    Seaberg E, Belle S, Beringer K. Liver transplantation in the United States from 1987–1998: updated results from the Pitt-UNOS Liver Transplant Registry. Los Angeles, CA: UCLA Tissue Typing Laboratory, 1998.
  • 36
    Regev A, Reddy RK, Torres MB, et al. Racial differences in outcome of liver transplantation in patients with HCV cirrhosis [abstract 390]. Hepatology 2000; 32 (Suppl. 1): 259A.
  • 37
    Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004; 117: 1638.
  • 38
    Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 45561.
  • 39
    McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 10619.
  • 40
    Düsing R. Adverse events, compliance, and changes in therapy. Curr Hypertens Rep 2001; 3: 48892.
  • 41
    Weng FL, Israni AK, Joffe MM, et al. Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation. J Am Soc Nephrol 2005; 16: 183948.
  • 42
    Cossrow N, Falkner B. Race/ethnic issues in obesity and obesity-related comorbidities. J Clin Endocrinol Metab 2004; 89: 25904.
  • 43
    Gross J, Johnson S, the RENEW investigators. Double-dose peginterferon alfa-2b with weight-based ribavirin improves response for interferon/ribavirin non-responders with hepatitis C: final results of “RENEW” [abstract 60]. Hepatology 2005; 42 (Suppl. 1): 219A20A.
  • 44
    Pegasys® (peginterferon alfa-2a) [package insert]. Nutley, NJ: Hoffmann-La Roche Inc.; Updated January 2004. Available at Accessed February 23, 2007.
  • 45
    Lee DH, Jamal H, Regenstein FG, Perrillo RP. Morbidity of chronic hepatitis C as seen in a tertiary care medical center. Dig Dis Sci 1997; 42: 18691.
  • 46
    Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37: 44351.
  • 47
    Bonaccorso S, Marino V, Puzella A, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-α-based immunotherapy are related to interferon-α-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22: 8690.
  • 48
    Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36 (Suppl. 1): S23744.
  • 49
    Sulkowski MS. Anemia in the treatment of hepatitis C virus infection. Clin Infect Dis 2003; 37 (Suppl. 4): S31522.
  • 50
    Afdhal NH, Dieterich DT, et al. and the PROACTIVE Study Group. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126: 130211.
  • 51
    Howell CD, Jeffers LS, Cassidy W, Reddy KR, Hu S, Lee JS. Peginterferon alfa-2a and ribavirin for chronic hepatitis C genotype 1 infections in black patients: safety, tolerability and impact on sustained virologic response. J Viral Hepat 2006; 13: 3716.
  • 52
    Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve Clin J Med 2004; 71 (Suppl. 3): S1721.
  • 53
    Bekkering FC, Brouwer JT, Leroux-Roels G, Van VH, Elewaut A, Schalm SW. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. J Hepatol 1998; 28: 9604.
  • 54
    Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science 1998; 282: 1037.
  • 55
    Herrmann E, Neumann AU, Schmidt JM, Zeuzem S. Hepatitis C virus kinetics. Antivir Ther 2000; 5: 8590.
  • 56
    Layden TJ, Layden JE, Ribeiro RM, Perelson AS. Mathematical modeling of viral kinetics: a tool to understand and optimize therapy. Clin Liver Dis 2003; 7: 16378.
  • 57
    Layden-Almer JE, Ribeiro RM, Wiley T, Perelson AS, Layden TJ. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology 2003; 37: 134350.
  • 58
    Coleman CL. Transmission of HIV/AIDS among African American intravenous drug users: implication for public health policy. ABNF J 2004; 15: 946.
  • 59
    Brown SL, O'Connell L. Restricted access to care: the role of race, managed care, and type of insurance. J Health Care Finance 2004; 31: 2637.
  • 60
    Osborn BL, Olsen HS, Nardelli B, et al. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-a fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 2002; 303: 5408.
  • 61
    Keeffe EB, Hollinger FB.Consensus Interferon Study Group Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group. Hepatology 1997; 26: 101S7S.
  • 62
    Leevy C, Chalmers C, Blatt M. Comparison of African American and non-African American patient sustained virologic response in peg-IFN alpha 2+weight-based ribavirin nonresponders retreated with IFN alfacon-1+IFN gamma-1b [abstract 1267]. Hepatology 2005; 42 (Suppl. 1): 698A.
  • 63
    Chang CC, Chen TT, Cox BW, et al. Evolution of a cytokine using DNA family shuffling. Nat Biotechnol 1999; 17: 7937.
  • 64
    Gish RG. Treating HCV with ribavirin analogues and ribavirin-like molecules. J Antimicrob Chemother 2006; 57: 813.
  • 65
    Benhamou Y, Pockros P, Rodriguez-Torres M, et al. The safety and efficacy of viramidine plus PegIFN alfa-2b versus ribavirin plus PegIFN alfa-2b in therapy-naïve patients infected with HCV: phase 3 results (VISER1) [abstract 751]. Presented at the 41st annual meeting of the European Association for the Study of the Liver, Vienna, Austria, April 26–30, 2006.
  • 66
    Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 2002; 1: 34755.
  • 67
    Jubin R. Hepatitis C IRES: translating translation into a therapeutic target. Curr Opin Mol Ther 2001; 3: 27887.
  • 68
    Kapadia SB, Brideau-Andersen A, Chisari FV. Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci USA 2003; 100: 20148.
  • 69
    Reesink HW, Zeuzem S, Van Vliet A, et al. Initial results of a phase 1b, multiple-dose study of VX-950, a hepatitis C protease inhibitor [abstract 527]. Gastroenterology 2005; 128 (Suppl. 2): A-697.
  • 70
    Godofsky E, Afdhal N, Rustgi V, et al. First clinical results for a novel antiviral treatment for hepatitis C: a phase I/II dose escalation trial assessing tolerance, pharmacokinetics, and antiviral activity of NM283 [abstract 96]. J Hepatol 2004; 40 (Suppl. 1): 35.
  • 71
    Afdhal N, Rodriguez-Torres M, Lawitz E, et al. Enhanced antiviral efficacy for valopicitabine (NM283) plus peg-interferon in hepatitis C patients with HCV genotype-1 infection: results of a phase IIa multicenter trial [abstract 93]. J Hepatol 2005; 41 (Suppl. 1): A93.